Skip to content

Oruka Therapeutics, Inc. ORKA Lease Liability Payments - Remainder of Fiscal Year

Lease Liability Payments - Remainder of Fiscal Year at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s lease liability payments - remainder of fiscal year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s lease liability payments - remainder of fiscal year?
Oruka Therapeutics, Inc. (ORKA) reported lease liability payments - remainder of fiscal year of $768K in Q1 2026.
How has Oruka Therapeutics, Inc.'s lease liability payments - remainder of fiscal year changed year-over-year?
Oruka Therapeutics, Inc.'s lease liability payments - remainder of fiscal year increased by 55.5% year-over-year, from $494K to $768K.
What does lease liability payments - remainder of fiscal year mean?
The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.